David W. Goodrich

How the other half lives, the amino-terminal domain of the retinoblastoma tumor suppressor protein.

The retinoblastoma tumor-suppressor gene, the exception that proves the rule.

The Thoc1 ribonucleoprotein and prostate cancer progression.

Evaluating Effects of Hypomorphic Thoc1 Alleles on Embryonic Development in Rb1 Null Mice.

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

An approach for controlling the timing and order of engineered mutations in mice.

Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells.

Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.

Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance.

Pan-cancer molecular analysis of the RB tumor suppressor pathway.

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in -Mutant Non-small Cell Lung Cancer.

Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression.

Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer.

Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity.

A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.

Retinoblastoma Protein Paralogs and Tumor Suppression.